← All trials
NCT00405704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2007
- Primary completion
- Jun 1, 2013
- Completion date
- May 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 607
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- University of KansasOverall official - principal investigator
- Children's National Medical CenterOverall official - principal investigator
- University of WisconsinOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- University of AlabamaOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- Wake Forest UniversityOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- State University of New York, BuffaloOverall official - principal investigator
- Oregon Health and Science UniversityOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- Northeast Ohio Medical UniversityOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Pennsylvania State UniversityOverall official - principal investigator
- University of TennesseeStudy chair
- Thomas Jefferson UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.